Skip to main content
SpringerLink
Log in

Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

We recently demonstrated in humans that the extent of low-dose aspirin (LDA)-induced gastropathy was directly related to the individual gastric acid secretion level. We also established reliable cutoff serum pepsinogen (PG) values to predict gastric acid secretion status. In this study, we investigated the clinical usefulness of measuring the serum pepsinogen values for identifying a high-risk group for gastric mucosal injury among chronic LDA users.

Methods

One hundred long-term LDA users were enrolled in this analysis. Serum from each subject was subjected to determination of H. pylori status and measurement of pepsinogen values. According to our recent report, a PG I value ≥ 50 ng/mL was defined as estimated hyperchlorhydria in H. pylori-negative subjects, while a PG I/II ≥ 3.3 was defined as estimated hyperchlorhydria in H. pylori-positive subjects. The grade of gastric mucosal injury was assessed endoscopically, and multiple logistic regression analyses were used to estimate the risk.

Results

Estimated hyperchlorhydria was a strong independent risk for intensive gastric mucosal injury with an OR (95 % CI): 34.0 (4.5–259) and for gastric ulcer with an OR (95 % CI): 10.2 (1.8–58.3) in H. pylori-positive subjects, while it was not a significant risk in H. pylori-negative subjects. The association persisted even after excluding those with conventional risks for LDA-gastropathy such as ulcer histories.

Conclusion

Using simple serum measurement of H. pylori antibody and pepsinogen concentrations, an extremely high-risk group for LDA-induced gastropathy could be extracted, and these patients should become a therapeutic target for prevention of LDA-induced gastropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

CI:

Confidence interval

EH:

Estimated hyperchlorhydria

GI:

Gastrointestinal

LDA:

Low-dose aspirin

OR:

Odds ratio

PG:

Pepsinogen

PPI:

Proton pump inhibitor

References

  1. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin––what’s the risk? Aliment Pharmacol Ther. 2006;24:897–908.

    Article  CAS  PubMed  Google Scholar 

  2. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26:125–40.

    Article  CAS  PubMed  Google Scholar 

  3. Lanas A, Polo-Tomás M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator––a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37:738–48.

    Article  CAS  PubMed  Google Scholar 

  4. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105:2533–49.

    Article  PubMed  Google Scholar 

  5. Bhatt DL, Scheiman J, Abraham NS, American College of Cardiology Foundation; American College of Gastroenterology; American Heart Association, et al. ACCF, ACG, AHA expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;2008(103):2890–907.

    Article  Google Scholar 

  6. Sugano K, Choi MG, Lin JT, On behalf of the LAVENDER Study Group, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2013;. doi:10.1136/gutjnl-2013-304722.

    PubMed  Google Scholar 

  7. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2011;46:724–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sanuki T, Fujita T, Kutsumi H, Care Study Group, et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol. 2012;47:1186–97.

    Article  CAS  PubMed  Google Scholar 

  9. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97:797–802.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.

    Article  CAS  PubMed  Google Scholar 

  11. Ho CW, Tse YK, Wu B, Mulder CJ, Chan FK. The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study. Aliment Pharmacol Ther. 2013;37:819–24.

    Article  CAS  PubMed  Google Scholar 

  12. Rowe PH, Starlinger MJ, Kasdon E, Hollands MJ, Silen W. Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. Gastroenterology. 1987;93:863–71.

    CAS  PubMed  Google Scholar 

  13. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996;23:432–4.

    Article  CAS  PubMed  Google Scholar 

  14. Iijima K, Ara N, Abe Y, et al. Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy. J Gastroenterol. 2011;46:612–9.

    Article  CAS  PubMed  Google Scholar 

  15. Samloff IM. Cellular localization of group I pepsinogen in human gastric mucosa by immunofluorescence. Gastroenterology. 1971;61:185–8.

    CAS  PubMed  Google Scholar 

  16. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973;65:36–42.

    CAS  PubMed  Google Scholar 

  17. Samloff IM, Secrist DM, Passaro E. A study of relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology. 1975;69:1196–200.

    CAS  PubMed  Google Scholar 

  18. Derakhshan MH, El-Omar E, Oien K, et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J Clin Pathol. 2006;59:1293–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori-negative and -positive Japanese subjects. J Gastroenterol. 2005;40:938–44.

    Article  CAS  PubMed  Google Scholar 

  20. Iijima K, Koike T, Abe Y, Shimosegawa T. Cutoff serum pepsinogen values for predicting gastric acid secretion status. Tohoku J Exp Med. 2014;232(4):293–300.

    Article  CAS  PubMed  Google Scholar 

  21. Iijima K, Ara N, Abe Y, et al. Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level. J Gastroenterol. 2012;47:1290–7.

    Article  CAS  PubMed  Google Scholar 

  22. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci. 1990;35:1494–9.

    Article  CAS  PubMed  Google Scholar 

  23. Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med. 2011;223:35–44.

    Article  CAS  PubMed  Google Scholar 

  24. Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999;94:2094–9.

    Article  CAS  PubMed  Google Scholar 

  25. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.

    CAS  PubMed  Google Scholar 

  26. Iijima K, Ohara S, Koike T, Sekine H, Shimosegawa T. Gastric acid secretion of normal Japanese subjects in relation to H. pylori infection, aging, and gender. Scand J Gastroenterol. 2004;39:709–16.

    Article  CAS  PubMed  Google Scholar 

  27. Shiotani A, Sakakibara T, Yamanaka Y, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol. 2009;44:717–25.

    Article  CAS  PubMed  Google Scholar 

  28. Malfertheiner P, Megraud F, O’Morain CA, European Helicobacter Study Group, et al. Management of Helicobacter pylori infection––the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–64.

    Article  CAS  PubMed  Google Scholar 

  29. Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144:528–35.

    Article  CAS  PubMed  Google Scholar 

  30. Iijima K, Ara N, Abe Y, et al. Association of gastric acid and mucus secretion level with low-dose aspirin-induced gastropathy. J Gastroenterol. 2012;47:150–8.

    Article  CAS  PubMed  Google Scholar 

  31. Iijima K, Iwabuchi T, Ara N, et al. Reactive increase in gastric mucus secretion is an adaptive defense mechanism against low-dose aspirin-induced gastropathy. Dig Dis Sci. 2013;58:2266–74.

    Article  CAS  PubMed  Google Scholar 

  32. Konturek JW, Dembinski A, Stoll R, Domschke W, Konturek SJ. Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation. Gut. 1994;35:1197–204.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection. Gastroenterology. 2008;135:41–60.

    Article  CAS  PubMed  Google Scholar 

  34. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261–70.

    Article  CAS  PubMed  Google Scholar 

  35. Tozawa K, Oshima T, Okugawa T, et al. A Randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014 [Epub ahead of print].

  36. Sostres C, Gargallo CJ. Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26(2):141–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, 980-8574, Japan

    K. Iijima, T. Koike, N. Ara, K. Nakagawa, Y. Kondo, K. Uno, W. Hatta, N. Asano, A. Imatani & T. Shimosegawa

Authors
  1. K. Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Ara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Uno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Imatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T. Shimosegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Iijima.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iijima, K., Koike, T., Ara, N. et al. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol 50, 305–312 (2015). https://doi.org/10.1007/s00535-014-0976-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-014-0976-5

Keywords

Search

Navigation